Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling ...

Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy ofOxford BioDynamics' EpiSwitch blood-based Colorectal No-Stool Test (NST) High ...

This test has the potential ability to detect early cancers and precancerous polyps with greater accuracy." Dr Alexandre Akoulitchev, OBD's Chief Scientific Officer added: "Reliable and non ...

81% for early cancer stages and 82% for non-cancerous polyps. Linking the top diagnostic biomarkers to nearby genes, OBD used the EpiSwitch KnowledgeBase platform to map pathways that help ...